Drug Trial Radar · NCT00471705
Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.
Last checked: Nov 20, 2026Latest source record: Jan 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
437
Actual
Start
Jun 2006
Primary completion
Aug 2008
Study completion Dec 2009
Sponsor
- Lead sponsor
- Universidad de AntioquiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Dirección de Sanidad del Ejército de Colombia (DISAN); Ministerio de Salud y Protección Social, Colombia
- First posted
- May 10, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cutaneous leishmaniasis (CL) is a worldwide disease, endemic in 88 countries, that has shown an increasing incidence the last two decades. It is estimated that in 2005, about of 20,000 new cases of CL were diagnosed in Colombia. So far, pentavalent antimony compounds have been considered the treatment of choice with a percentage of cure of about 85%. However, the high efficacy of these drugs is counteracted by their adverse events and disadvantages. Previous studies have shown that miltefosine could be a potential alternative of treatment for CL. The main objective of this study is to evaluate the efficacy and safety of miltefosine or thermotherapy for the treatment for CL. In this study the efficacy of oral treatment of miltefosine 150 mg/day for 28 days or a thermotherapy device used for one session at 50 celsius degrees during 30 seconds will be compared with the standard treatment of intramuscular injections of 20 mg/Kg/day of pentavalent antimonials (GlucantimeÒ) for 20 days in CL parasitologically proven patients. This trial will be conducted according to the International approved GCP (Good Clinical Practice) guidelines.
Conditions
- Cutaneous Leishmaniasis
Interventions
MiltefosineDrug
Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
ThermotherapyDevice
One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
Glucantime®Drug
Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Clinical ResponseTime frame: Until 6 months posttreatment
- FailureTime frame: Until 3 months posttreatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Program for Research and Control in Tropical Diseases - PECET
Medellín, Antioquia, Colombia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.